Corcept Therapeutics Inc
CORT
Market Cap$6.37B
Close$
$82.76
36.2% upside
Current Fair Value
36.2% upsideUndervalued by 36.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.37 Billion |
|---|---|
| Enterprise Value | $6.28 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $1.02 |
| Beta | 0.46 |
| Outstanding Shares | 103,371,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 44.47 |
|---|---|
| PEG | 88.11 |
| Price to Sales | 10.13 |
| Price to Book Ratio | 10.13 |
| Enterprise Value to Revenue | 9.99 |
| Enterprise Value to EBIT | 43.78 |
| Enterprise Value to Net Income | 44 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Corcept Therapeutics Inc
CEO: Joseph Belanoff Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved...